Reading view
WaterCopilot: An AI-Driven Virtual Assistant for Water Management
GI-Bench: A Panoramic Benchmark Revealing the Knowledge-Experience Dissociation of Multimodal Large Language Models in Gastrointestinal Endoscopy Against Clinical Standards
Moral Lenses, Political Coordinates: Towards Ideological Positioning of Morally Conditioned LLMs
ISLA: A U-Net for MRI-based acute ischemic stroke lesion segmentation with deep supervision, attention, domain adaptation, and ensemble learning
MCP Bridge: A Lightweight, LLM-Agnostic RESTful Proxy for Model Context Protocol Servers
Efficient and Reproducible Biomedical Question Answering using Retrieval Augmented Generation
Aligning Trustworthy AI with Democracy: A Dual Taxonomy of Opportunities and Risks
STAT+: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash
This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.
You’re back. We’re sort of back. It’s Day 2 of JPM and we’re definitely not exhausted or delirious yet.
This is Elaine Chen, Adam Feuerstein, Matt Herper, and Allison DeAngelis again. We’ve got a lot more news today, so let’s get to it.
The next test for Kite Pharma — and Gilead
It’s anito-cel, the CAR-T therapy for multiple myeloma that Gilead is developing in partnership with Arcellx. Gilead submitted the therapy to the FDA sometime before the end of December, Cindy Perettie, executive vice president of Kite Pharma, the cell therapy division of Gilead, told STAT at a Gilead media breakfast.
Continue to STAT+ to read the full story…


© Alex Hogan/STAT
Doctors think AI has a place in healthcare — but maybe not as a chatbot
STAT+: OpenEvidence promises ‘medical super-intelligence’ at JPM. What is it?
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
OpenEvidence promises ‘medical super-intelligence’
It will be hard for OpenEvidence to top its 2025. The company announced nearly $500 million in funding last year and seemingly overnight became a go-to tool in the medical profession. A slide during the company’s Monday JPM presentation claims that queries to the company’s clinical evidence chatbot grew from 2.6 million in 2024 to 17.9 million in December 2025, with well over 100 million queries for the year.
The company also revealed it will be launching “medical super-intelligence.” What does that mean? Katie Palmer explains in a new story.
Continue to STAT+ to read the full story…


© Adobe